A polygenic risk score for breast cancer risk in a Taiwanese population
- 724 Downloads
Multiple common variants identified by genome-wide association studies showed limited evidence of the risk of breast cancer in Taiwan. In this study, we analyzed the breast cancer risk in relation to 13 individual single-nucleotide polymorphisms (SNPs) identified by a GWAS in an Asian population.
In total, 446 breast cancer patients and 514 healthy controls were recruited for this case–control study. In addition, we developed a polygenic risk score (PRS) including those variants significantly associated with breast cancer risk, and also evaluated the contribution of PRS and clinical risk factors to breast cancer using receiver operating characteristic curve (AUC).
Logistic regression results showed that nine individual SNPs were significantly associated with breast cancer risk after multiple testing. Among all SNPs, six variants, namely FGFR2 (rs2981582), HCN1 (rs981782), MAP3K1 (rs889312), TOX3 (rs3803662), ZNF365 (rs10822013), and RAD51B (rs3784099), were selected to create PRS model. A dose–response association was observed between breast cancer risk and the PRS. Women in the highest quartile of PRS had a significantly increased risk compared to women in the lowest quartile (odds ratio 2.26; 95% confidence interval 1.51–3.38). The AUC for a model which contained the PRS in addition to clinical risk factors was 66.52%, whereas that for a model which with established risk factors only was 63.38%.
Our data identified a genetic risk predictor of breast cancer in Taiwanese population and suggest that risk models including PRS and clinical risk factors are useful in discriminating women at high risk of breast cancer from those at low risk.
KeywordsBreast cancer Polygenic risk score Common variants Risk prediction
This study was supported by the Health and Welfare Surcharge of Tobacco Products, Ministry of Health and Welfare to the Comprehensive Cancer Center of Taipei Medical University (MOHW105-TDU-B-212-134001), Taipei Medical University Hospital (103TMU-TMUH-09), Taipei Medical University (TMU102-AE1-B03), and the Top University Project- Cancer Translational Center of Taipei Medical University.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Health Promotion Administration MOHAW. Health indicator 123. https://olap.hpa.gov.tw/en_US/index.aspx. Accessed May 5 2016
- 24.Efron B, Tibshirani R (1997) Improvements on cross-validation: the 632+ bootstrap method. J Am Stat Assoc 92:548–560Google Scholar